JP2002508737A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508737A5
JP2002508737A5 JP1998511892A JP51189298A JP2002508737A5 JP 2002508737 A5 JP2002508737 A5 JP 2002508737A5 JP 1998511892 A JP1998511892 A JP 1998511892A JP 51189298 A JP51189298 A JP 51189298A JP 2002508737 A5 JP2002508737 A5 JP 2002508737A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1998511892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508737A (ja
Filing date
Publication date
Priority claimed from US08/704,473 external-priority patent/US5830850A/en
Application filed filed Critical
Publication of JP2002508737A publication Critical patent/JP2002508737A/ja
Publication of JP2002508737A5 publication Critical patent/JP2002508737A5/ja
Pending legal-status Critical Current

Links

JP51189298A 1996-08-28 1997-08-28 骨粗鬆症を含む骨吸収障害を治療するための方法および組成物 Pending JP2002508737A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/704,473 1996-08-28
US08/704,473 US5830850A (en) 1996-08-28 1996-08-28 Methods for the treatment of bone resorption disorders, including osteoporosis
PCT/US1997/015121 WO1998008494A1 (en) 1996-08-28 1997-08-28 Methods and compositions for the treatment of bone resorption disorders, including osteoporosis

Publications (2)

Publication Number Publication Date
JP2002508737A JP2002508737A (ja) 2002-03-19
JP2002508737A5 true JP2002508737A5 (https=) 2005-04-07

Family

ID=24829667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51189298A Pending JP2002508737A (ja) 1996-08-28 1997-08-28 骨粗鬆症を含む骨吸収障害を治療するための方法および組成物

Country Status (6)

Country Link
US (1) US5830850A (https=)
EP (1) EP0961613A4 (https=)
JP (1) JP2002508737A (https=)
AU (1) AU4165797A (https=)
CA (1) CA2264715A1 (https=)
WO (1) WO1998008494A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
SK48198A3 (en) * 1995-10-30 1998-10-07 Smithkline Beecham Corp Cathepsin k molecule, a peptid being bonded to the hollow of active positon of cathepsin k, a composition, method for identification of inhibiting compound and inhibitors being competitively bonded to the active position of cathepsin k
WO1997016433A1 (en) * 1995-10-30 1997-05-09 Smithkline Beecham Corporation Protease inhibitors
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
JP4268684B2 (ja) * 1997-09-24 2009-05-27 第一三共株式会社 骨代謝異常症の診断方法
US20030044399A1 (en) * 1998-12-23 2003-03-06 Smithkline Beecham Corporation Method of treatment
US20030144175A1 (en) * 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2000061785A2 (en) * 1999-04-14 2000-10-19 Smithkline Beecham Corporation Polynucleotide and polypeptide sequences of monkey cathepsin k
US20040214889A1 (en) * 1999-07-31 2004-10-28 Smithkline Beecham Corporation Calcilytic compounds
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
WO2001034600A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
JP2003513971A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
JP2001158736A (ja) * 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 骨関節疾患の予防及び改善剤
EP2095817A1 (en) * 1999-12-07 2009-09-02 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
AU2001243441B2 (en) * 2000-03-21 2004-11-25 Smithkline Beecham Corporation Protease inhibitors
AU2001272981A1 (en) * 2000-06-22 2002-01-02 Genaissance Pharmaceuticals, Inc. Haplotypes of the slc26a2 gene
US7332494B2 (en) * 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
EP1309591B1 (en) * 2000-08-14 2007-01-24 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
US6369032B1 (en) * 2000-09-06 2002-04-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies
US20030073672A1 (en) * 2001-09-05 2003-04-17 Breitenbucher J. Guy Method for treating allergies using substituted pyrazoles
US7799326B2 (en) * 2001-09-24 2010-09-21 Mount Sinai School Of Medicine Methods and compositions for cathespin k complex-mediated disorders
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
EP1585750B1 (en) * 2002-12-09 2008-10-15 Arizona Board Of Regents Narcistatin prodrugs
US20060020001A1 (en) * 2002-12-23 2006-01-26 Allan Shepard Use of cathepsin k inhibitors for the treatment of glaucoma
WO2005089736A2 (en) * 2004-03-05 2005-09-29 The Arizona Board Of Regents, On Behalf Of, Arizona State University Methods for treating inflammatory and autoimmune diseases
WO2009076490A1 (en) * 2007-12-12 2009-06-18 Velcura Therapeutics, Inc. Use of cathepsin l antagonists in the treatment of bone disease
CN105456292B (zh) * 2009-10-30 2019-03-26 北卡罗来纳大学教堂山分校 来自肝外胆管树的专能干细胞及其分离方法
WO2013037770A1 (en) * 2011-09-15 2013-03-21 Bayer Intellectual Property Gmbh Method for the continuous production of water-dispersible vinyl polymers
NZ627896A (en) 2012-01-27 2016-11-25 Biomarin Technologies B V Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5158936A (en) * 1986-12-22 1992-10-27 Syntex (U.S.A.) Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
ATE117375T1 (de) * 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US5399349A (en) * 1992-02-06 1995-03-21 Paunescu; Calin Treatment of acne
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US5501969A (en) * 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Similar Documents

Publication Publication Date Title
JP2000502280A5 (https=)
JP2000501018A5 (https=)
JP2000500076A5 (https=)
JP2000500055A5 (https=)
JP2000500026A5 (https=)
JP2001505091A5 (https=)
JP2000502472A5 (https=)
JP2000500874A5 (https=)
JP2000502485A5 (https=)
JP2000502425A5 (https=)
JP2001509835A5 (https=)
JP2000502568A5 (https=)
JP2000511425A5 (https=)
JP2000500912A5 (https=)
JP2000502570A5 (https=)
JP2000508259A5 (https=)
JP2000501876A5 (https=)
JP2002508737A5 (https=)
JP2000508653A5 (https=)
JP2001516519A5 (https=)
JP2000515085A5 (https=)
JP2000509217A5 (https=)
JP2001501019A5 (https=)
JP2000501229A5 (https=)
JP2000502316A5 (https=)